[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2017, Vol. 39 ›› Issue (6): 482-490.doi: 10.16288/j.yczz.16-357

• Review • Previous Articles     Next Articles

Research progress on genetic heterogeneity between primary and paired metastatic colorectal cancer

Youwang Lu1(),Kunhua Wang1,2,3()   

  1. 1. Faculty of Medical , Kunming University of Science and Technology, Kunming 650500, China
    2. Department of Gastrointestinal and Hernia surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650500, China
    3. Yunnan Institute of Digestive Disease, The First Affiliated Hospital of Kunming Medical University, Kunming 650500, China
  • Received:2016-12-22 Revised:2017-04-05 Online:2017-06-20 Published:2017-04-28
  • Supported by:
    the Foundation of Yunnan Institute of Digestive Disease(2016NS001,2016NS003,2016NS004);the Scientific Research Project of Yunnan Provincial Bureau of Education(2015J054);The Major project of Yunnan Provincial Bureau of Education(ZD2015010)

Abstract:

Colorectal cancer (CRC) is one of the leading causes of cancer deaths in China. A standard practice in treating metastatic CRC (mCRC) is to predict benefits of the anti-EGFR monoclonal antibody treatment based on the somatic mutation spectrum. Because metastatic samples are difficult to obtain clinically, primary tumors are normally used instead. However, due to the genetic heterogeneity between primary and paired metastatic tumors, primary site biopsy always underrepresents the mutational landscape of metastatic sites. Currently, the extent of genetic heterogeneity between primary and paired mCRC is still under debate. Here, we review comparative studies of primary and matched mCRC and discuss the underlying causes and potential strategies.

Key words: colorectal cancer, genetic heterogeneity, primary site, metastases site